The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

As demand for COVID-19 vaccines increases, Big Pharma offers its manufacturing capacity and expertise.

Big Pharma Takes on Vaccine Production

Both companies will provide resources and expertise to research, develop, and manufacture multiple mRNA vaccine candidates, including multi-valent and monovalent approaches. 

GSK and CureVac to Collaborate on Next-Generation COVID-19 Vaccines

More work is needed to educate businesses on the value of innovation and the availability of funding.

Continued Innovation is Key for COVID-19 Recovery

Sean Milmo is a freelance writer based in Essex, UK.

The EC intends to get tougher on issues such as reliability of drug supplies, particularly essential medicines.

Getting Tough on Supplies

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

COVID-19 vaccine supplies are breaking news headlines, in both ‘good’ and ‘not so good’ ways.  

In Short Supply

Mike Hennessy, Sr., is the founder and chairman of MJH Life Sciences.

Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.

How Pharmaceutical Innovation is Saving the World

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

A complicated vaccination rollout and mixed messages may derail the pandemic endgame.

A Hopeful but Dangerous Phase

The companies previously entered into a collaboration in November 2020 with the goal of producing more than 100 million doses of the CureVac vaccine per year at Rentschler’s Laupheim, Germany facility.

CureVac and Rentschler Accelerate COVID-19 Vaccine Manufacturing

Contract development and manufacturing organizations provide vital services to rush COVID-19 vaccines to patients.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success